Results 221 to 230 of about 1,399,448 (251)

Nonvariceal Upper GI Bleeding in Established Users of Proton-Pump Inhibitors: Higher Incidence But Better Outcomes. [PDF]

Clin Transl Gastroenterol
Taha AS, McCloskey C, Craigen T, Angerson WJ.   +3 more
europepmc   +1 more source

Dispensing of actionable pharmacogenetic drugs among adults receiving cardiovascular disease medications in the Northern Netherlands: A serial cross‐sectional study

Clinical Pharmacology &Therapeutics, EarlyView.
The extent of pharmacogenetic (PGx) drug dispensing among Dutch adults receiving medications for cardiovascular disease (CVD) is unknown. Using the University of Groningen IADB.nl pharmacy database, we performed a serial cross‐sectional study (2019–2023) to estimate the annual prevalence of PGx drug dispensing and annual rates of initiation.
Zhuolin Zhang, Guiling Zhou, Jens H. J. Bos, Eelko Hak, Talitha Feenstra, Frank Klont   +5 more
wiley   +1 more source

Renal Outcomes With Potassium-Competitive Acid Blockers Versus Proton Pump Inhibitors in CKD. [PDF]

Kidney Int Rep
Kim SY, Lee H, Kim JS, Kim JH, Jeon HL.
europepmc   +1 more source

Should proton pump inhibitors be used for glucocorticoid-related upper gastrointestinal bleeding prevention in patients with autoimmune liver disease? A real-world cohort study. [PDF]

Front Immunol
Zhang R, Cui L, Ding D, Guo G, Guo C, Jia G, Shang Y, Han Y.   +7 more
europepmc   +1 more source

The effect of the use of proton pump inhibitors (PPI) on complications in patients with cirrhosis. [PDF]

BMC Gastroenterol
Atasoy H, Levent A.
europepmc   +1 more source

Old Drugs, New Targets: Molecular Docking Insights into Repurposing Proton Pump Inhibitors for the TLR4/MD-2, NLRP3, and C5aR1 Axes in Autoimmune Liver Diseases. [PDF]

Pharmaceuticals (Basel)
Yıldız M, Şeker E, Altınkaya E, Poustforoosh A, Tüzün B, Ataseven H.   +5 more
europepmc   +1 more source

Proton pump inhibitors in invasively ventilated patients with SARS-CoV-2: a substudy of the re-evaluating the inhibition of stress erosions trial. [PDF]

BMJ Open
Dennis B, Heels-Ansdell D, Ibrahim Q, Basmaji J, Thabane L, Guyatt G, Saunders L, Hand L, Loy O, Zytaruk N, Hardie M, Deane AM, Marshall JC, Arabi Y, Lauzier F, Dionne JC, Burns KE, Alhazzani W, Vazquez-Grande G, Geagea A, Myburgh J, Muscedere J, English S, Binnie A, Tsang JL, Hunt M, Ostermann M, Al-Fares AA, Knowles S, Ahmed A, Cook DJ, REVISE Investigators and the Canadian Critical Care Trials Group.   +31 more
europepmc   +1 more source

Proton-pump inhibitors and palbociclib or abemaciclib in endocrine-sensitive breast cancer treatment. [PDF]

Sci Rep
Takada S, Takahashi K, Uozumi R, Mukohara T, Hayashida T, Iwabe M, Iihara H, Kusuhara-Mamishin K, Tahatsu K, Kitagawa Y, Tsuchiya M, Kitahora M, Umehara K, Nagayama A, Kosaka S, Asano-Niwa Y, Watanabe K, Seki T, Ohnuki K, Futamura M, Kawazoe H, Nakamura T.   +21 more
europepmc   +1 more source